Thyroid-stimulating hormone receptor-stimulating autoantibody (TSI) (TSI)

Thyroid-stimulating hormone receptor-stimulating autoantibodies (TSIs) are pathogenic IgG immunoglobulins that act as functional agonists of the thyroid-stimulating hormone receptor (TSHR) (StatPearls, 2023). In patients with Graves' disease, these autoantibodies mimic the action of the pituitary hormone TSH, leading to the constitutive activation of the TSHR on thyroid follicular cells (PubMed, PMID: 31210468). This bypasses the normal pituitary-thyroid feedback loop, resulting in the overproduction of thyroxine and triiodothyronine, which causes clinical hyperthyroidism. Beyond the thyroid gland, TSIs also interact with TSHR expressed in orbital fibroblasts and pretibial myxedema tissues, contributing to the pathogenesis of Graves' ophthalmopathy and dermopathy (Journal of Clinical Endocrinology & Metabolism, 2020). Therapeutic interventions targeting these autoantibodies include B-cell depletion therapies like Rituximab and novel monoclonal antibodies such as K1-70, which directly block the autoantibody's binding site on the receptor (ClinicalTrials.gov, NCT02904395). Monitoring the levels of these antibodies is essential for diagnosing autoimmune thyroid disease and predicting clinical outcomes in pregnant patients and those undergoing antithyroid drug therapy.

Other names

Thyroid-stimulating immunoglobulinTSILong-acting thyroid stimulatorLATSTSH receptor antibodyTRAbThyroid-stimulating antibodyTSAb

Reduction of autoantibody production through B-cell depletion, physical removal from circulation via plasmapheresis, or competitive inhibition of receptor binding.